Sesques, P., Ferrant, E., Safar, V., Wallet, F., Tordo, J., Dhomps, A., Karlin, L., Brisou, G., Vercasson, M., Hospital‐Gustem, C., Schwiertz, V., Ranchon, F., Rioufol, C., Choquet, M., Sujobert, P., Ghergus, D., Bouafia, F., Golfier, C., Lequeu, H., Lazareth, A., Novelli, S., Devic, P., Traverse Glehen, A., Viel, S., Venet, F., Mialou, V., Hequet, O., Chauchet, A., Arkam, Y., Nicolas‐Virelizier, E., Peyrade, F., Cavalieri, D., Ader, F., Ghesquières, H., Salles, G., & Bachy, E. (n.d.). commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. American journal of hematology, 95(11), 1324–1333. http://access.bl.uk/ark:/81055/vdc_100114048269.0x00002b